menu

Pulmonary Arterial Hypertension A Deeper Dive

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Pulmonary Arterial Hypertension A Deeper Dive

close
1.00 credits
60 minutes
Pulmonary Arterial Hypertension A Deeper Dive
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first webinar provides an in-depth discussion of the new definitions and diagnostic recommendations for PAH, along with the emerging data on the optimal management of patients with PAH. The second webinar early next year will provide a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.

  • Disclosure of Conflicts of Interest

    FACULTY AND PEER REVIEWER DISCLOSURES

    • Dr. Channick has disclosed the following relevant financial relationships: Consultant - Actelion, Bayer, Gossamer, Theravance. Contracted Research - Bayer
    • Dr. McLaughlin has disclosed the following relevant financial relationships: Consultant - Acceleron, Actelion, Altavant, Caremark, CiVi Biopharma, Gossamer Bio, Liquida, United Therapeutics. Contracted Research - Acceleron, Actelion, Gilead, Reata Phar, SonoVie, United Therapeutics
    • Nadine Al-Naamani, MD, MS - Peer Reviewer: has no financial relationships to disclose.

    AKH STAFF AND PLANNERS DISCLOSURES

    • Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has no financial relationships to disclose.
    • Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    • Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    • Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    • Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose. 

    ATS STAFF DISCLOSURES
    Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose.

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclosure Declaration
    It is the policy of ATS and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

    Copyright 2020 ATS and AKH Inc. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.

    Privacy Policy:
    https://akhcme.com/akhcme/pages/privacy

  • Target Audience

    This activity is designed for providers who participate in the care of patients with pulmonary hypertension including general pulmonologists, cardiologists, thoracic surgeons, internal medicine, primary care, and other subspecialty providers, physicians-in-training, nurses including nurse navigators, nurse practitioners, and physician extenders.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Identify the 2018 World Symposium on Pulmonary Hypertension new thresholds for the normal range of pulmonary artery pressure to be used in the diagnosis of pulmonary hypertension.
    • Delineate the diagnostic tests, NYHA and WHO classifications, and differential diagnostic considerations to provide a diagnosis of PAH.
    • Develop treatment strategies for optimal management of patients with PH/PAH.
  • Accreditation and Credit Designation Statements

    CME Credit provided by The American Thoracic Society

    Physicians
    CME Accreditation Statement

    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME Credit Designation Statement

    The American Thoracic Society designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Nurses
    AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
    This activity is awarded 1 Contact Hours.

    Nurse Practitioners

    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
    This activity is approved for 1 contact hour(s) which includes 0.5 hour(s) of pharmacology. Activity ID # 22027
    This activity was planned in accordance with AANP Accreditation Standards and Policies.

    Criteria for Success
    Statements of credit will be awarded based on the participant reviewing activity, scoring a 70% or higher on the post test, and completing and submitting an activity evaluation. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Bayer HealthCare Pharmaceuticals Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first webinar provides an in-depth discussion of the new definitions and diagnostic recommendations for PAH, along with the emerging data on the optimal management of patients with PAH. The second webinar early next year will provide a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.

  • Disclosure of Conflicts of Interest

    FACULTY AND PEER REVIEWER DISCLOSURES

    • Dr. Channick has disclosed the following relevant financial relationships: Consultant - Actelion, Bayer, Gossamer, Theravance. Contracted Research - Bayer
    • Dr. McLaughlin has disclosed the following relevant financial relationships: Consultant - Acceleron, Actelion, Altavant, Caremark, CiVi Biopharma, Gossamer Bio, Liquida, United Therapeutics. Contracted Research - Acceleron, Actelion, Gilead, Reata Phar, SonoVie, United Therapeutics
    • Nadine Al-Naamani, MD, MS - Peer Reviewer: has no financial relationships to disclose.

    AKH STAFF AND PLANNERS DISCLOSURES

    • Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has no financial relationships to disclose.
    • Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    • Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    • Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    • Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose. 

    ATS STAFF DISCLOSURES
    Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose.

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclosure Declaration
    It is the policy of ATS and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

    Copyright 2020 ATS and AKH Inc. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.

    Privacy Policy:
    https://akhcme.com/akhcme/pages/privacy

  • Target Audience

    This activity is designed for providers who participate in the care of patients with pulmonary hypertension including general pulmonologists, cardiologists, thoracic surgeons, internal medicine, primary care, and other subspecialty providers, physicians-in-training, nurses including nurse navigators, nurse practitioners, and physician extenders.

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Identify the 2018 World Symposium on Pulmonary Hypertension new thresholds for the normal range of pulmonary artery pressure to be used in the diagnosis of pulmonary hypertension.
    • Delineate the diagnostic tests, NYHA and WHO classifications, and differential diagnostic considerations to provide a diagnosis of PAH.
    • Develop treatment strategies for optimal management of patients with PH/PAH.
  • Accreditation and Credit Designation Statements

    CME Credit provided by The American Thoracic Society

    Physicians
    CME Accreditation Statement

    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME Credit Designation Statement

    The American Thoracic Society designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Nurses
    AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
    This activity is awarded 1 Contact Hours.

    Nurse Practitioners

    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
    This activity is approved for 1 contact hour(s) which includes 0.5 hour(s) of pharmacology. Activity ID # 22027
    This activity was planned in accordance with AANP Accreditation Standards and Policies.

    Criteria for Success
    Statements of credit will be awarded based on the participant reviewing activity, scoring a 70% or higher on the post test, and completing and submitting an activity evaluation. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Bayer HealthCare Pharmaceuticals Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 6/21/21